Fortrea (FTRE) Projected to Announce Quarterly Earnings on Thursday

Key Points

• Fortrea is expected to report Q3 2026 results before market open on October 29. Analysts forecast earnings of $0.2172 per share on revenue of $671.57 million.
• The company’s previous quarter exceeded expectations, with EPS of $0.23 versus the $0.18 consensus and revenue of $678.20 million compared with $647.57 million expected.
• FTRE shares have risen 5.6% and trade near their 12-month high, while analyst sentiment remains mixed: the consensus rating is “Hold” with a $22.80 price target, despite several recent upgrades and one downgrade.

Fortrea (NASDAQ:FTRE - Get Free Report) is projected to issue its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Fortrea to post earnings of $0.2172 per share and revenue of $671.57 million for the quarter. Investors can check the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:00 AM ET.

Fortrea (NASDAQ:FTRE - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.05. The company had revenue of $678.20 million during the quarter, compared to the consensus estimate of $647.57 million. Fortrea had a negative net margin of 3.18% and a positive return on equity of 10.72%. On average, analysts expect Fortrea to post $0.86 EPS for the current fiscal year and $1.04 EPS for the next fiscal year.

Fortrea Trading Up 5.6%

FTRE opened at $24.06 on Thursday. The stock has a market capitalization of $2.29 billion, a P/E ratio of -26.44, a P/E/G ratio of 0.55 and a beta of 1.93. Fortrea has a 12 month low of $8.55 and a 12 month high of $24.37. The firm's fifty day simple moving average is $19.45 and its 200 day simple moving average is $16.72. The company has a current ratio of 0.96, a quick ratio of 0.96 and a debt-to-equity ratio of 1.98.

Insider Buying and Selling at Fortrea

In other news, CEO Anshul Thakral sold 99,869 shares of the firm's stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $19.16, for a total transaction of $1,913,490.04. Following the completion of the transaction, the chief executive officer directly owned 316,797 shares of the company's stock, valued at $6,069,830.52. This trade represents a 23.97% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.73% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on FTRE. Robert W. Baird set a $23.00 target price on shares of Fortrea in a research note on Thursday, July 30th. Zacks Research downgraded Fortrea from a "hold" rating to a "strong sell" rating in a research note on Monday, October 12th. TD Cowen lifted their price target on Fortrea from $19.00 to $23.00 and gave the company a "buy" rating in a research note on Tuesday, August 4th. Truist Financial boosted their price target on Fortrea from $19.00 to $26.00 and gave the company a "buy" rating in a report on Thursday, July 30th. Finally, Wall Street Zen upgraded Fortrea from a "hold" rating to a "buy" rating in a report on Saturday, October 10th. Seven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $22.80.

Fortrea Company Profile

Fortrea Holdings Inc is a global contract research organization (CRO) that provides services to pharmaceutical, biotechnology and medical device companies. The company helps clients plan, manage and execute clinical development programs, supporting the testing of new medicines and therapies from early-stage research through regulatory approval and post-approval activities.

Its services include Phase I through Phase IV clinical trials, clinical operations, patient recruitment and access, data management, biostatistics, medical monitoring, pharmacovigilance and regulatory support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.